Can-Fite BioPharma (CANF) Other Non-Current Assets (2014 - 2018)
Can-Fite BioPharma's (CANF) quarterly Other Non-Current Assets came in at $2000.0 in Q4 2018, down 60.0% YoY from $5000.0 in Q4 2017, and down 60.0% on a QoQ basis from $5000.0 in Q4 2017.
Can-Fite BioPharma (CANF) Other Non-Current Assets (2014 - 2018) Analysis & Trends
Can-Fite BioPharma (CANF) has 4 years of Other Non-Current Assets data on file, last reported at $2000.0 in Q4 2018.
- Quarterly Other Non-Current Assets fell 60.0% year-over-year to $2000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $2000.0 (down 60.0% YoY) and the FY2018 annual result came in at $2000.0, down 60.0% from the prior year.
- Other Non-Current Assets fell to $2000.0 in Q4 2018, from $5000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $12000.0 in Q1 2014 to a low of $2000.0 in Q4 2018.
- A 4-year average of $7250.0 and a median of $7500.0 in 2016 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2017 — Other Non-Current Assets sank 50.0% — and 2018, when it sank 60.0%.
- Tracing CANF's Other Non-Current Assets over 4 years: stood at $12000.0 in 2014, then fell by 16.67% to $10000.0 in 2016, then slumped by 50.0% to $5000.0 in 2017, then slumped by 60.0% to $2000.0 in 2018.
- The last three Other Non-Current Assets figures came in at $2000.0 (Q4 2018), $5000.0 (Q4 2017), and $10000.0 (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2,000.00 |
| Dec 31, 2017 | 5,000.00 |
| Dec 31, 2016 | 10,000.00 |
| Mar 31, 2014 | 12,000.00 |